These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25759023)

  • 21. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical application of companion diagnostics.
    Jørgensen JT
    Trends Mol Med; 2015 Jul; 21(7):405-7. PubMed ID: 26141798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histological tumor typing in the age of molecular profiling.
    Klauschen F; Heim D; Stenzinger A
    Pathol Res Pract; 2015 Dec; 211(12):897-900. PubMed ID: 26589872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the NCI MATCH trial a match for gynecologic oncology?
    Moore KN; Mannel RS
    Gynecol Oncol; 2016 Jan; 140(1):161-6. PubMed ID: 26586415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A; Massard C; Soria JC
    Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolution of computational hemodynamics as a clinical tool in decision making, patient specific treatment and clinical management. Part II.
    Gallo D; Anayiotos A; Morbiducci U
    Ann Biomed Eng; 2015 Jun; 43(6):1273-4. PubMed ID: 25986956
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of genomics on personalized cancer medicine.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying multi-hit carcinogenic gene combinations: Scaling up a weighted set cover algorithm using compressed binary matrix representation on a GPU.
    Al Hajri Q; Dash S; Feng WC; Garner HR; Anandakrishnan R
    Sci Rep; 2020 Feb; 10(1):2022. PubMed ID: 32029803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico drug repositioning: what we need to know.
    Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
    Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Drug Repurposing Accelerate Precision Oncology?
    Schipper LJ; Zeverijn LJ; Garnett MJ; Voest EE
    Cancer Discov; 2022 Jul; 12(7):1634-1641. PubMed ID: 35642948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations About the Use of Biomarkers in Cancer Clinical Trials.
    Chabner BA
    Clin Pharmacol Ther; 2018 Jan; 103(1):25-27. PubMed ID: 29134628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop.
    Sakellaropoulos T; Hur J; Melas IN; Guo EY; Alexopoulos L; Bohlooly M; Bai JP
    Adv Protein Chem Struct Biol; 2016; 102():147-79. PubMed ID: 26827605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 37. DrugTargetInspector: An assistance tool for patient treatment stratification.
    Schneider L; Stöckel D; Kehl T; Gerasch A; Ludwig N; Leidinger P; Huwer H; Tenzer S; Kohlbacher O; Hildebrandt A; Kaufmann M; Gessler M; Keller A; Meese E; Graf N; Lenhof HP
    Int J Cancer; 2016 Apr; 138(7):1765-76. PubMed ID: 26501925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of personalized therapies for anticancer treatment.
    Vazquez A
    BMC Syst Biol; 2013 Apr; 7():31. PubMed ID: 23587292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer driver drug interaction explorer.
    Hartung M; Anastasi E; Mamdouh ZM; Nogales C; Schmidt HHHW; Baumbach J; Zolotareva O; List M
    Nucleic Acids Res; 2022 Jul; 50(W1):W138-W144. PubMed ID: 35580047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Repurposing in the Development of Anticancer Agents.
    Olgen S; Kotra LP
    Curr Med Chem; 2019; 26(28):5410-5427. PubMed ID: 30009698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.